Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544881 | 0.86 | PANK3 (0.53) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2102828 | 0.84 | L3MBTL1 (0.71) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10223333 | 0.84 | MAPT (0.64) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL19701980 | 0.82 | MAPT (0.57) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5544811 | 0.82 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14220699 | 0.82 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5544806 | 0.82 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10288811 | 0.82 | PANK3 (0.58) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10169298 | 0.82 | MAPT (0.71) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL23544857 | 0.81 | PANK3 (0.65) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | L3MBTL1 4396/4885MAPT 3409/4885ALDH1A1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.